...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: 4-8b guess

 

I agree absolutely that a buyout of everything to do with CVD, diabetes, CKD, PAH, and cognitive function would make most sense for a single large company. But RVX could (and in my opinion should) hang onto HIV.

 

 

 

If RVX where to continue as a smaller company, where would the continuing cash come from?  The big shareholders would demand a dividend, means double income tax for most, once at company level and at shareholder level (for those not in a deferred accounts).

 

Buy out or partner, same issue, where does RVX raise cash, even if partner pays new P3 study.  RVX burn rate is near 1M a month without new P3 costs.  Buyout is only real option.

 

Why no PR, best guess, they are talking to BP, signed a confidentially agreement, neither party able release discussions. 

 

My recall may be at issue here, since RVX meet with FDA on Nov 13th, and stated there is a 30 day hold?  Would make Dec 13th a big day for FDA meeting.

 

Believe a complete buy out is in order, lots to offer BP, including 20 something new compounds waiting.

 

This is all MHO, no data to support, just speculation.   A buyout with both cash and stock might be beneficial for both buyer and stockholders.  Price, hope it is in US $.

I have great respect to all on this forum.  I can only imagine RVX employees are wondering about their future.  BP should also consider the value employees bring to the table.  Much to consider.

Share
New Message
Please login to post a reply